Home

Features

  • The Battle of the Blockbusters: GLP-1 AgonistsByPatricia Van Arnum

    The Battle of the Blockbusters: GLP-1 Agonists
    By

    GLP-1 agonist drugs, in the form of Novo Nordisk’s Wegvoy/Ozempic, and Lilly’s Mounjaro for weight management and treating Type II diabetes, were blockbuster winners in 2023, putting this therapeutic sector into high focus. What has been the impact on manufacturing and what are other contenders in this high-growth sector?


  • Manufacturing & Supply Lines: Small-Molecule APIsByPatricia Van Arnum

    Manufacturing & Supply Lines: Small-Molecule APIs
    By

    Small-molecule drugs still dominate new drug approvals, as measured by the number of new molecular entities approved by the FDA’s Center for Drug Evaluation and Research, but are they translating into market success? DCAT Value Chain Insights takes a look on the market for drugs with small-molecule active pharmaceutical ingredients and related supply–demand fundamentals.


DCAT MEMBER COMPANY COMMUNITY